Abstract
Background
Congenital Myasthenic Syndromes (CMS) are heterogeneous genetic diseases.
Case characteristics
Two siblings presented with progressive limb girdle weakness without significant fluctuations or ocular muscle weakness. Repetitive nerve stimulation showed a decremental response and there was no response to pyridostigmine therapy.
Outcome
A trial of salbutamol produced a remarkable, consistent improvement. Mutation in exon 5 of the DOK7 gene was found in both siblings.
Message
Patients with congenital myasthenic syndrome with DOK 7 mutation benefit remarkably with salbutamol.
Similar content being viewed by others
References
Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord. 2012;22:99–111.
Beeson D, Higuchi O, Palace J, Cossins J, Spearman H, Maxwell S, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006;313:1975–8.
Abicht A, Müller JS, Lochmüller H. Congenital Myasthenic Syndromes. 2003 May 9 [Updated 2012 Jun 28]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1168/
Müller JS, Herczegfalvi A, Vilchez JJ, Colomer J, Bachinski LL, Mihaylova V, et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain. 2007;130:1497–506.
Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R, et al. Clinical features of the DOK7 neuromuscular Junction synaptopathy. Brain. 2007;130:1507–15.
Mahjneh I, Lochmüller H, Muntoni F, Abicht A. DOK7 limb-girdle myasthenic syndrome mimicking congenital muscular dystrophy. Neuromuscul Disord. 2013;23:36–42.
Selcen D, Milone M, Shen XM, Harper CM, Stans AA, Wieben ED, et al. Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients. Ann Neurol 2008; 64:71–87.
Hamuro J, Higuchi O, Okada K, Ueno M, Iemura S, Natsume T, et al. Mutations causing DOK7 congenital myasthenia ablate functional motifs in Dok-7. J Biol Chem. 2008;283:5518–24.
Yamanashi Y, Higuchi O, Beeson D. Dok7/MuSK signaling and a congenital myasthenic syndrome. Acta Myologica. 2008;27:25–9.
Witting N, Vissing J. Pharmacologic treatment of downstream of tyrosine kinase 7 congenital myasthenic syndrome. JAMA Neurol. 2014;71:350–4.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khadilkar, S., Bhutada, A., Nallamilli, B. et al. Limb girdle weakness responding to salbutamol: An Indian family with DOK7 mutation. Indian Pediatr 52, 243–244 (2015). https://doi.org/10.1007/s13312-015-0616-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-015-0616-z